Skip to main content
122 search results for:

ASCO 2020 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. play
    04-06-2020 | ASCO 2020 | Conference coverage | Video

    Expert highlights: Genitourinary cancers at ASCO 2020

    Axel Merseburger takes us through his picks of the genitourinary cancers track of the virtual 2020 ASCO Annual Meeting, including the JAVELIN Bladder 100 and KEYNOTE-426 trials (10:28).

  2. play
    02-06-2020 | ASCO 2020 | Conference coverage | Video

    Expert highlights: Breast cancer at ASCO 2020

    Bora Lim rounds up the breast cancer studies that caught her attention at the virtual 2020 ASCO Annual Meeting, including the MONALEESA pooled ctDNA analysis and the BYLieve trial (7:04).

  3. play
    03-06-2020 | ASCO 2020 | Conference coverage | Video

    Expert highlights: Lung cancer immuno-oncology at ASCO 2020

    Erin Schenk highlights some of the lung cancer immuno-oncology studies that you may have missed at the virtual 2020 ASCO Annual Meeting (8:23).

  4. play
    25-02-2020 | Renal cell carcinoma | Conference coverage | Video

    Metastatic RCC updates from ASCO GU 2020

    Bernard Escudier and Viktor Grünwald take us through the metastatic renal cell carcinoma studies that caught their attention at the 2020 Genitourinary Cancers Symposium, including long-term data from the CheckMate 214 trial and studies of novel agents such as the HIF-2α inhibitor MK-6482 and sitravatinib. This independent video was supported by an educational grant from Pfizer and Merck KGaA.

  5. 15-02-2020 | Image

    Shilpa Gupta | ASCO GU 2020

  6. play
    16-02-2020 | ASCO GU 2020 | Conference coverage | Video

    Expert highlights from ASCO GU 2020

    Axel Merseburger takes us through the studies that caught his attention at ASCO GU 2020, including the NIMBUS trial and first-in-human study of the HIF-2α inhibitor MK-6482 (3:24).

  7. play
    25-02-2020 | Renal cell carcinoma | Conference coverage | Video

    Treatment options for advanced RCC: Updates from ASCO GU 2020

    Axel Merseburger and Laurence Albigès discuss the treatment options for patients with advanced renal cell carcinoma and highlight some of the novel data presented at the 2020 Genitourinary Cancers Symposium that may affect practice in the future. This independent video was supported by an educational grant from Pfizer and Merck KGaA.

  8. 20-04-2023 | Urothelial cancer | At a glance | Article

    At a glance: Second and later line immunotherapy for advanced urothelial carcinoma

    The findings were subsequently published in The New England Journal of Medicine  in 2020 and led to the 2020 US FDA approval  of maintenance avelumab in this patient population at a recommended dose of 800 mg every 2 weeks.

  9. 08-06-2022 | ASCO 2022 | Conference coverage | Article

    Overall survival benefits shown for capivasertib in AI-resistant breast cancer

    The updated analysis of the phase 2 trial was presented by Robert Jones (Cardiff University, UK) at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA.

  10. 06-05-2020 | ASCO 2020 | Channel

    Lung cancer at ASCO 2020

  11. 06-05-2020 | ASCO 2020 | Channel

    GU cancers at ASCO 2020

  12. 22-06-2021 | ASCO 2021 | Conference coverage | Article

    COVID-19: Remote patient monitoring proves effective for outpatient management

    However, please refer to your own professional and governmental guidelines for the latest guidance in your own country. 2021 ASCO Annual Meeting; 4–8 June (Abstract 12000) 2021 ASCO Annual Meeting; 4–8 June (Abstract 1503) JCO Oncol Pract 2021; doi:10.1200/OP.21.00307 2021 ASCO Annual Meeting; 4–8 June (Abstract 1504) JCO Oncol Pract 2021; doi:10.1200/OP.21.00269

  13. 19-02-2020 | ASCO GU 2020 | News | Article

    EV-103 update bolsters enfortumab vedotin–pembrolizumab potential in urothelial carcinoma

    Jonathan Rosenberg video asco CTA At the time of analysis, the median duration of response was not reached, and 53.7% of participants had a response lasting at least 1 year.

  14. 16-06-2021 | ASCO 2021 | Conference coverage | Article

    Immunotherapy linked to improved metastatic small-cell urothelial cancer survival

    The investigators identified 102 patients who received systemic therapy for metastatic SCUC at their institution between April 2006 and June 2020.

  15. 04-05-2021 | Lung and thoracic tumors | At a glance | Article

    At a glance: The JAVELIN lung cancer trials

    As published in the Journal for ImmunoTherapy of Cancer in 2020 , the ORR was 19.9%, median progression-free survival (PFS) was 4.0 months, and median overall survival (OS) was 14.1 months.

  16. 12-02-2021 | ASCO GU 2021 | Conference coverage | Article

    COVID-19: More evidence against protective effect of ADT

    Daniel Kwon (University of California, San Francisco, USA) and co-investigators therefore queried the University of California Health COVID Research Data Set – a centralized database for five academic medical centers and 12 affiliated hospitals – to identify 5211 men with prostate cancer who underwent SARS-CoV-2 testing between February and December 2020.

  17. play
    01-06-2020 | ASCO 2020 | Conference coverage | Video

    Researcher comment: Initial data from CCC19

    ASCO 2020: Jeremy Warner presents the initial data from the CCC19 registry of cancer patients with comorbid COVID-19.

  18. 22-04-2020 | Comorbidities | News | Article
    News in brief

    ASCO launches cancer and COVID-19 registry

    ASCO has initiated the ASCO Survey on COVID-19 in Oncology Registry to collect point-in-time and longitudinal data on the outcomes of patients with cancer and comorbid COVID-19.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.